Obesity surgery in patients with end-stage organ failure: Is it worth it?

被引:2
|
作者
Billeter, Adrian T. [1 ]
Zumkeller, Michael [1 ]
Brock, Judith [2 ,3 ]
Herth, Felix [2 ,3 ]
Zech, Ulrike [4 ]
Zeier, Martin [5 ]
Rupp, Christian [6 ]
Wagenlechner, Petra [7 ]
Mehrabi, Arianeb [1 ]
Mueller-Stich, Beat P. [1 ]
机构
[1] Heidelberg Univ Hosp, Dept Gen Visceral & Transplant Surg, Neuenheimer Feld 420, D-69120 Heidelberg, Germany
[2] Heidelberg Univ Hosp, Thoraxklin, Dept Pneumol & Crit Care Med, Heidelberg, Germany
[3] Heidelberg Univ Hosp, Translat Lung Res Ctr Heidelberg TLRCH, Heidelberg, Germany
[4] Heidelberg Univ Hosp, Dept Endocrinol & Metab, Heidelberg, Germany
[5] Heidelberg Univ Hosp, Dept Nephrol, Heidelberg, Germany
[6] Heidelberg Univ Hosp, Dept Gastroenterol Infect Dis & Intoxicat, Heidelberg, Germany
[7] Heidelberg Univ Hosp, Dept Gen Internal & Psychosomat Med, Heidelberg, Germany
关键词
Organ failure; High-risk; Obesity surgery; Metabolic surgery; VENTRICULAR EJECTION FRACTION; QUALITY-OF-LIFE; BARIATRIC SURGERY; SLEEVE GASTRECTOMY; HEART-FAILURE; OUTCOMES; MORTALITY; RISK; COMPLICATIONS; ASSOCIATION;
D O I
10.1016/j.soard.2021.11.012
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Little is known about the long-term outcomes of patients with end-stage organ failure (ESOF) undergoing obesity surgery. Objective: To investigate the perioperative and mid-term outcomes of patients with ESOF undergoing obesity surgery. Setting: University hospital, Germany. Methods: A total of 1 094 patients undergoing obesity surgery from 2006 to 2019 were screened. Inclusion criteria were ejection fraction <30%, continuous oxygen/noninvasive ventilation therapy, liver cirrhosis, or kidney failure stage 4/5. ESOF patients were compared with matched standard (MS) patients without advanced organ failure and matched for age, gender, body mass index (BMI), operation type, diabetes, arterial hypertension, and sleep apnea. Results: Twenty-seven ESOF patients (56% female, age 50.3 +/- 8.6, BMI 53.8 +/- 8.7 kg/m(2)) were identified. Eighty-five percent had a sleeve gastrectomy. Mid-term total weight loss was 26.6% +/- 9.0% in the ESOF patients versus 17.8% +/- 11.1% in MS patients (P = .181). Long-term improvement of type 2 diabetes was comparable (ESOF: HbA1C 8.79 +/- 2.06% to 6.25 +/- 1.17%, P = .047; MS: HbA1C 7.94 +/- 2.02% to 7.2 +/- 1.28%; P = .343). Depression scores (Patient Health Questionnaire 9) among ESOF patients improved from 13.0 +/- 6.3 to 6.1 +/- 5.8 (P = .004) but without significant change in MS patients (9.4 +/- 7.3 to 4.3 +/- 5.7; P = .082). Lung function improved in all patients although only 15% were off oxygen therapy. Treatment goals were achieved in >50% of the other groups. Major complications occurred in 11% (ESOF) versus 4% (MS) of patients (P = .299) with one death in the ESOF group (4%). Conclusion: Both groups had similar outcomes regarding weight loss and co-morbidity improvement. Depression only improved significantly in the ESOF group. Patients with ESOF should not be precluded from obesity surgery. Further investigation is needed to define optimized selection criteria. (C) 2021 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:495 / 503
页数:9
相关论文
共 50 条
  • [21] Preoperative risk factor of multiple organ failure following LVAS implantation in patients with end-stage heart failure
    Hiroyuki, N
    Sawa, Y
    Fukushima, N
    Matsumiya, G
    Monta, O
    Hata, H
    Matsuda, H
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (05) : S172 - S172
  • [22] MitraClip in end-stage heart failure: a realistic alternative to surgery?
    van den Heuvel, Ad F. M.
    Alfieri, Ottavio
    Mariani, Massimo A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (05) : 472 - 474
  • [23] Kidney Transplantation and Bariatric Surgery for Morbidly Obese Patients with End-Stage Renal Failure
    Petrochenkov, Egor
    Martinino, Alessandro
    Bencini, Giulia
    Myint, Lucas S.
    Spaggiari, Mario
    Di Cocco, Pierpaolo
    Benedetti, Enrico
    Tzvetanov, Ivo G.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S496 - S497
  • [24] CORONARY ANGIOGRAPHY AND HEART-SURGERY IN PATIENTS WITH END-STAGE RENAL-FAILURE
    GROSSMANN, R
    GLUNZ, HG
    SEYBOLDEPTING, W
    ALBERT, FW
    MEDIZINISCHE KLINIK, 1986, 81 (20) : 627 - 631
  • [25] The Taiwan experience - surgery for end-stage myocardial failure in Taiwan
    Chu, SH
    PARTIAL LEFT VENTRICULECTOMY: ITS THEORY, RESULTS AND PERSPECTIVES, 1998, 1173 : 95 - 98
  • [26] The reasons for the failure of the primary arteriovenous fistula surgery in patients with end-stage renal disease
    Cheng, Qian
    Zhao, Yang Jiu
    JOURNAL OF VASCULAR ACCESS, 2015, 16 : S74 - S77
  • [27] Bariatric Surgery and Long-term Survival in Patients With Obesity and End-stage Kidney Disease
    Sheetz, Kyle H.
    Gerhardinger, Laura
    Dimick, Justin B.
    Waits, Seth A.
    JAMA SURGERY, 2020, 155 (07) : 581 - 588
  • [28] Pharmacokinetics of pantoprazole in patients with end-stage renal failure
    Kliem, V
    Bahlmann, J
    Hartmann, M
    Huber, R
    Luhmann, R
    Wurst, W
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (05) : 1189 - 1193
  • [29] Inotropic therapy for end-stage heart failure patients
    Toma M.
    Starling R.C.
    Current Treatment Options in Cardiovascular Medicine, 2010, 12 (5) : 409 - 419
  • [30] Antiendomysial antibodies in patients with end-stage heart failure
    Prati, D
    Bardella, MT
    Peracchi, M
    Porretti, L
    Scalamogna, M
    Conte, D
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (01): : 218 - 219